EKF Diagnostics lifts margins and cash as it resets for five-year growth plan

EKF Diagnostics Holdings ( (GB:EKF) ) has shared an update.

EKF Diagnostics reported 2025 revenues of £51.6m, up from £50.2m, with gross margins rising to 51% and adjusted EBITDA increasing 9.3% to £12.4m as it exits non-core, low-margin product lines. The group generated £11.6m in operating cash, lifted net cash to £15.8m and returned £5m to shareholders via buybacks, while some funds remain restricted in Russia.

Point-of-care revenues grew to £33.0m, driven by higher hematology and diabetes sales, and Life Sciences revenues rose to £17.9m, including a 10% increase in β-HB sales. Management says 2025 marks the establishment of a five-year strategic development plan centred on business simplification, margin expansion and organic growth in hemoglobin point-of-care testing and Life Sciences, positioning EKF for accelerated, profit-focused expansion.

The company restructured its commercial teams, expanded marketing and significantly increased hematology analyser placements, which should underpin future consumables demand. EKF is also investing in additional cuvette production capacity, aiming to support higher volumes and reinforce its market position as it pursues long-term shareholder value through sustained cash generation and targeted reinvestment.

The most recent analyst rating on (GB:EKF) stock is a Hold with a £26.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Spark’s Take on EKF Stock

According to Spark, TipRanks’ AI Analyst, EKF is a Neutral.

EKF Diagnostics Holdings receives a score of 67, driven by strong financial performance and a positive earnings call. The company’s robust balance sheet and improved profitability are significant strengths. However, technical indicators suggest potential bearish momentum, and the valuation is moderate. The positive outlook from the earnings call, including strategic growth plans and a share buyback program, enhances the overall score.

To see Spark’s full report on EKF stock, click here.

More about EKF Diagnostics Holdings

EKF Diagnostics Holdings is an AIM-listed global diagnostics group focused on point-of-care analysers in hematology and diabetes, alongside Life Sciences services for specialist enzyme manufacturing and custom products used in diagnostic, food and industrial applications. Headquartered near Cardiff with five manufacturing sites in the U.S. and Germany, the company sells into more than 120 countries worldwide.

Average Trading Volume: 343,998

Technical Sentiment Signal: Strong Sell

Current Market Cap: £106.1M

See more insights into EKF stock on TipRanks’ Stock Analysis page.